Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in cSCC and CLL
NCT00563290Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2007
- Primary completion
- Apr 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in cutaneous squamous cell carcinoma (cSCC), chronic lymphocytic leukemia (CLL), sponsored by National Cancer Institute. Started Nov 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
cutaneous squamous cell carcinoma (cSCC)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00563290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563290.